Jeff Yass’s Moleculin Biotech MBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.3K Buy
+729
New +$16.2K ﹤0.01% 13257
2023
Q2
– Sell
-1
Closed -$10.7K – 12708
2023
Q1
$10.7K Buy
+1
New +$8.76K ﹤0.01% 12192
2020
Q1
– Sell
-3
Closed -$137K – 10619
2019
Q4
$137K Buy
+3
New +$140K ﹤0.01% 8990
2019
Q3
– Hold
0
– -$20K – 10560
2019
Q2
– Hold
0
– – – 10006
2017
Q3
– Sell
-1
Closed -$52K – 9292
2017
Q2
$52K Buy
+1
New +$43.5K ﹤0.01% 8877

Other funds holding MBRX

Jeff Yass's MBRX Position: Q3 2026 in Review

Jeff Yass opened a new position in Moleculin Biotech (MBRX) in Q3 2026: 729 shares worth $7.3K. The stake represents ﹤0.01% of the portfolio and ranks #13257 among its holdings. This is a return to the name: Jeff Yass previously reported a position in MBRX as recently as Q1 2023.

Jeff Yass first reported a position in MBRX in Q2 2017 and has held it in 4 quarters since. The position peaked at $137K in Q4 2019. 19 funds tracked by Wall St. Rank hold MBRX as of Q3 2026.

  • Jeff Yass held 729 shares of Moleculin Biotech worth $7.3K as of Q3 2026.
  • Moleculin Biotech was a new Jeff Yass position in Q3 2026.
  • Moleculin Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #13257 holding.
  • Jeff Yass first reported a position in Moleculin Biotech in Q2 2017 and has held it in 4 quarters since.
  • Jeff Yass's Moleculin Biotech position peaked at $137K in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.